Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]R.D. Jager, W.F. Mieler, J.W. Miller. Age-related macular degeneration . N Engl J Med 358, 2606-2617 (2008)

  • [2]R. Brookmeyer, E. Johnson, K. Ziegler-Graham, HM Arrighi. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3,186-191 (2007)

  • [3]E. Çerman, M. Eraslan, O. Çekiç. Age-related macular degeneration and Alzheimer disease. Turkish J Med Sci 45, 1004-1009 (2015)

  • [4]D.H. Anderson, K.C. Talaga, A.J. Rivest, E. Barron, G.S. Hageman, L.V. Johnson. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78, 243-256 (2004)

  • [5]H. Zając-Pytrus, A. Pilecka, Turno-Kręcicka, J. Adamiec-Mroczek, M. Misiuk-Hojło. The Dry Form of Age-Related Macular Degeneration (AMD): The Current Concepts of Pathogenesis and Prospects for Treatment. Adv Clin Exp Med 24, 1099-1104 (2015)

  • [6]M. Reinisalo, A. Kårlund, A. Koskela, K. Kaarniranta, R.O. Karjalainen. Polyphenol Stilbenes: Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related Diseases. Oxid Med Cell Longev 2015, 1-24 (2015)

  • [7]R.B. Nussenblatt, B. Liu, L. Wei, H.N. Sen. The immunological basis of degenerative diseases of the eye. Int Rev Immunol 32, 97-112 (2013)

  • [8]K. Kaarniranta, A. Salminen, A. Haapasalo, H. Soininen, M. Hiltunen. Age-related macular degeneration (AMD): Alzheimer's disease in the eye? J Alzheimer's Dis 24, 615-631 (2011)

  • [9]Age-related Eye Disease Study Research Group A-REDSR. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107, 2224-2232 (2000)

  • [10]P.L. Tan, C. Bowes Rickman, N. Katsanis. AMD and the alternative complement pathway: genetics and functional implications. Hum Genomics 10, 23 (2016)

  • [11]A.P. Ciardella, I.M. Donsoff, S.J. Huang, D.L. Costa, L.A. Yannuzzi. Polypoidal choroidal vasculopathy. Surv Ophthalmol 49, 25-37 (2004)

  • [12]C. Reitz, R. Mayeux. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88, 640-51 (2014)

  • [13]M. Baumgart, H.M. Snyder, M.C. Carrillo, S. Fazio, H. Kim, H. Johns. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement 11, 718-726 (2015)

  • [14]M. Prince, M. Guerchet, M. Prina. The Global Impact of Dementia 2013-2050. Alzheimer's Dis Int London (2013)

  • [15]M.C. Polidori, M. Marvardi, A. Cherubini, U. Senin, P. Mecocci. Heart disease and vascular risk factors in the cognitively impaired elderly: implications for Alzheimer's dementia . Aging (Milano) 13, 231-239 (2001)

  • [16]J.A. Schneider, P.A. Boyle, Z. Arvanitakis, J.L Bienias, D.A. Bennett. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol 62, 59-66 (2007)

  • [17]R.N. Kalaria, C. Ballard. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13 Suppl 3, S115-123 (1999)

  • [18]M. Ganguli, W.A. Kukull. Lost in Translation. Arch Neurol 67, 107 (2010)

  • [19]The Eye Diseases Prevalence Research Group*. Causes and prevalence of visual impairment among adults in the united states. Arch Ophthalmol 122, 477-485 (2004)

  • [20]A. Laitinen, L. Laatikainen, T. Harkanen, S. Koskinen, A. Reunanen, A. Aromaa. Prevalence of major eye diseases and causes of visual impairment in the adult Finnish population: A nationwide population-based survey . Acta Ophthalmol 88, 463-471 (2010)

  • [21]M.A. Bamashmus, B. Matlhaga, G.N. Dutton. Causes of blindness and visual impairment in the West of Scotland. Eye (Lond) 18, 257-261 (2004)

  • [22]J.R. Evans, A.E. Fletcher, R.P.L. Wormald, Community MRCT of A and M of OP in the. Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of Older People in the Community. Br J Ophthalmol 88, 365-370 (2004)

  • [23]D.S. Friedman, B.J. O'Colmain, B. Muñoz, S.C. Tomany, C. McCarty, P.T.V.M. de Jong, B. Nemesure, P. Mitchell, J. Kempen, Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122, 564-572 (2004)

  • [24]W.L. Wong, X. Su, X. Li, C.M.G. Cheung, R. Klein, C.Y. Cheng, T.Y. Wong. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis . Lancet Glob Heal 2, e106-e116 (2014)

  • [25]H.R. Coleman, C-C. Chan, F.L. Ferris, E.Y. Chew. Age-related macular degeneration. Lancet (London, England) 372, 1835-1845 (2008)

  • [26]C.W. Wong, Y. Yanagi, W-K. Lee, Y. Ogura, I. Yeo, T.Y. Wong, C.M.G. Cheung. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53, 107-139 (2016)

  • [27]R. Mayeux, Y. Stern. Epidemiology of Alzheimer Disease. Cold Spring Harb Perspect Med 2, 1-2(8) (2012)

  • [28]A.R. Rudnicka, Z. Jarrar, R. Wormald, D.G. Cook, A. Fletcher, C.G. Owen. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: A meta-analysis. Ophthalmology 119, 571-580 (2012)

  • [29]B.C. Riedel, P.M. Thompson, R.D. Brinton. Age, APOE and sex: Triad of risk of Alzheimer's disease. J Steroid Biochem Mol Biol 160, 134-147 (2016)

  • [30]J.M. Seddon, J. Cote, W.F. Page, S.H. Aggen, M.C. Neale. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol (Chicago, Ill 1960) 123, 321-327 (2005)

  • [31]J.N. Cooke Bailey, J.D. Hoffman, R.J. Sardell, W.K. Scott, M.A. Pericak-Vance, J.L Haines. The Application of Genetic Risk Scores in Age-Related Macular Degeneration: A Review. J Clin Med 5, 31 (2016)

  • [32]P.N. Baird, E. Guida, D.T. Chu, H.T.V. Vu, R.H. Guymer. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration . Invest Ophthalmol Vis Sci 45, 1311-1315 (2004)

  • [33]M.W. Logue, M. Schu, B.N. Vardarajan, J. Farrell, K.L Lunetta, G. Jun, C.T. Baldwin, M.M. DeAngelis, L.A. Farrer. A search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways. Neurobiol Aging 35, 1510 (2014)

  • [34]A.N. Tsiloulis, F. Zacharaki, M.G. Kotoula, D.Z. Chatzoulis, M.A. Morrison, K. Mayne, E. Dardiotis, I.L Stefanidis, P. Almpanidou, M.M. DeAngelis, E.E. Tsironi. Genetic variants in complement pathway and ARMS2/HTRA1 genes and risk of age-related macular degeneration in a homogeneous population from central Greece. Ophthalmic Genet 1-6 (2016)

  • [35]S.J. Woo, J. Ahn, M.A. Morrison, S.Y. Ahn, J. Lee, K.W. Kim, M.M. DeAngelis, K.H. Park. Analysis of genetic and environmental risk factors and their interactions in Korean patients with age-related macular degeneration. PLoS One 10, 1-14 (2015)

  • [36]M. Zetterberg, S. Landgren, M.E. Andersson, M.S. Palmér, D.R Gustafson, I. Skoog, L. Minthon, D.S Thelle, A. Wallin, N. Bogdanovic, N. Andreasen, K. Blennow, H. Zetterberg. Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 147B, 720-726 (2008)

  • [37]J.M. Seddon, R. Reynolds, Y. Yu, M.J. Daly, B. Rosner. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 118, 2203-2211 (2011)

  • [38]P. Proitsi, M.K. Lupton, F. Dudbridge, M. Tsolaki, G. Hamilton, M. Daniilidou, M. Pritchard, K. Lord, B.M. Martin, D. Craig, S Todd, B McGuinness, P Hollingworth, D Harold, I Kloszewska, H Soininen, P. Mecocci, B Velas, M Gill, B Lawlor, DC Rubinsztein, C Brayne, PA Passmore, J Williams, S Lovestone, JF Powell. Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiol Aging 33, 1843 (2012)

  • [39]B.N. Vardarajan, Y. Zhang, J.H. Lee, R. Cheng, C. Bohm, M. Ghani, C. Reitz, D. Reyes-Dumeyer, Y. Shen, E. Rogaeva, St George-Hyslop P, R. Mayeux. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol 77, 215-227 (2015)

  • [40]J.M. Butler, U. Sharif, M. Ali, M. McKibbin, J.P Thompson, R. Gale, Y.C. Yang, C. Inglehearn, L. Paraoan. A missense variant in CST3 exerts a recessive effect on susceptibility to age-related macular degeneration resembling its association with Alzheimers disease. Hum Genet 705-715 (2015)

  • [41]J.D. Hoffman, M.J.J.P. van Grinsven, C. Li, M Brantley, J McGrath, A Agarwal, WK Scott, SG Schwartz, J Kovach, M Pericak-Vance, CI Sanchez, JL Haines. Genetic Association Analysis of Drusen Progression. Investig Opthalmology Vis Sci 57, 2225 (2016)

  • [42]R Klein, BE Klein, SE Moss. Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol 147,103-110 (1998)

  • [43]B Neuner, A Komm, J Wellmann, M Dietzel, D Pauleikhoff, J Walter, M Busch, H-W Hense. Smoking history and the incidence of age-related macular degeneration--results from the Muenster Aging and Retina Study (MARS) cohort and systematic review and meta-analysis of observational longitudinal studies. Addict Behav 34, 938-947 (2009)

  • [44]TE Clemons, RC Milton, R Klein, JM Seddon, FL Ferris, Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 112, 533-539 (2005)

  • [45]W Xu, L Tan, H-F Wang, T Jiang, M-S Tan, L Tan, Q-F Zhao, J-Q Li, J Wang, J-T. Yu Meta-analysis of modifiable risk factors for Alzheimer's disease . J Neurol Neurosurg Psychiatry 86, 1299-1306 (2015)

  • [46]J Ye, Y-F Xu, J-J He, L-X Lou. Association between aspirin use and age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci 55, 2687-2696 (2014)

  • [47]VK Katsi, ME Marketou, DA Vrachatis, AJ Manolis, P Nihoyannopoulos, D Tousoulis, PE Vardas, I Kallikazaros. Essential hypertension in the pathogenesis of age-related macular degeneration: a review of the current evidence. J Hypertens 33, 2382-2388 (2015)

  • [48]R Klein, CE Myers, GHS Buitendijk, E Rochtchina, X Gao, PTVM de Jong, TA Sivakumaran, G Burlutsky, R McKean-Cowdin, A Hofman, SK Iyengar, KE Lee, BH Stricker, JR Vingerling, P Mitchell, BE Klein, CC Klaver, JJ Wang. Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. Am J Ophthalmol 158, 513-524 (2014)

  • [49]Z Arvanitakis, RS Wilson, JL Bienias, DA Evans, DA Bennett, Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function. Arch Neurol 61, 661 (2004)

  • [50]EL Abner, PT Nelson, RJ Kryscio, FA Schmitt, DW Fardo, RL Woltjer, NJ Cairns, L Yu, HH Dodge, C Xiong, K Masaki, SL Tyas, DA Bennett, JA Schneider, Z Arvanitakis. Diabetes is associated with cerebrovascular but not Alzheimer neuropathology. Alzheimers Dement 12(8), 882-889 (2016)

  • [51]X Chen, SS Rong, Q Xu, FY Tang, Y Liu, H Gu, POS Tam, LJ Chen, ME Brelén, CP Pang, C Zhao Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis. PLoS One 9(9), e108196 (2014)

  • [52]MK Ikram, P Mitchell, R Klein, AR Sharrett, DJ Couper, TY Wong. Age-related macular degeneration and long-term risk of stroke subtypes. Stroke 43, 1681-1683 (2012)

  • [53]AB Fernandez, TY Wong, R Klein, D Collins, G Burke, MF Cotch, B Klein, MM Sadeghi, Chen J. Age-Related Macular Degeneration and Incident Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. Ophthalmology 119, 765-770 (2012)

  • [54]AB Fernandez, GA Panza, B Cramer, S Chatterjee, R Jayaraman, W-C Wu. Age-Related Macular Degeneration and Incident Stroke: A Systematic Review and Meta-Analysis. PLoS One 10, e0142968 (2015)

  • [55]TDL Keenan, R Goldacre, MJ Goldacre. Associations between obstructive sleep apnoea, primary open angle glaucoma and age-related macular degeneration: record linkage study. Br J Ophthalmol, bjophthalmol-2015-308278 (2016)

  • [56]H Dolan, B Crain, J Troncoso, SM Resnick, AB Zonderman, RJ Obrien. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 68, 231-240 (2010)

  • [57]D-C Tsai, S-J Chen, C-C Huang, M-K Yuan, H-B Leu. Age-Related Macular Degeneration and Risk of Degenerative Dementia among the Elderly in Taiwan. Ophthalmology 122, 2327-2335 (2015)

  • [58]MA Williams, V Silvestri, D Craig, AP Passmore, G Silvestri. The prevalence of age-related macular degeneration in Alzheimer's disease. J Alzheimers Dis 42, 909-914 (2014)

  • [59]LH Curtis, BG Hammill, LG Qualls, LD Dimartino, F Wang, KA Schulman, SW Cousins. Treatment Patterns for Neovascular Age-Related Macular Degeneration: Analysis of 284 380 Medicare Beneficiaries. Am J Ophthalmol 153, 1116-1124 (2012)

  • [60]TDL Keenan, R Goldacre, MJ Goldacre. Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions. JAMA Ophthalmol 132, 63-68 (2014)

  • [61]P Tiraboschi, LA Hansen, LJ Thal, J Corey-Bloom. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1689 (2004)

  • [62]K Ohno-Matsui. Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res 30, 217-238 (2011)

  • [63]M Koronyo-hamaoui, Y Koronyo, A V Ljubimov, A Carol, MK Ko, KL Black, M Schwartz, DL Farkas. Plaques in a Mouse Model 1-27 (2012)

  • [64]CS Atwood, RN Martins, MA Smith, G Perry. Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 23, 1343-1350 (2002)

  • [65]JW Miller. Age-related macular degeneration revisited - Piecing the puzzle: The LXIX edward jackson memorial lecture . Am J Ophthalmol 155, 1-35 (2013)

  • [66]L Wang, ME Clark, DK Crossman, K Kojima, JD Messinger, JA Mobley, CA Curcio. Abundant Lipid and Protein Components of Drusen . PLoS One 5 (2010)

  • [67]IR Rodriguez, ME Clark, JW Lee, CA Curcio. 7-ketocholesterol accumulates in ocular tissues as a consequence of aging and is present in high levels in drusen. Exp Eye Res 128, 151-155 (2014)

  • [68]J.R. Dasari Prashanthi, G Marwarha., B.B Singh., O. B Ghribi. The oxysterol 27-hydroxycholesterol increases b-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol 10, 1e12 (2010)

  • [69]C Bowes Rickman, S Farsiu, CA Toth, M Klingeborn. Dry Age-Related Macular Degeneration: Mechanisms, Therapeutic Targets, and Imaging . Investig Opthalmology Vis Sci 54 Dec 13;54(14) (2013)

  • [70]FG Schlanitz, B Baumann, M Kundi, S Sacu, M Baratsits, U Scheschy, A Shahlaee, TJ Mittermüller, A Montuoro, P Roberts, M Pircher, CK Hitzenberger, U Schmidt-Erfurth. Drusen volume development over time and its relevance to the course of age-related macular degeneration. Br J Ophthalmol, bjophthalmol-2016-308422 (2016)

  • [71]NS Abdelfattah, H Zhang, DS Boyer, PJ Rosenfeld, WJ Feuer, G Gregori, SR Sadda. Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye. Invest Ophthalmol Vis Sci 57, 1839-1846 (2016)

  • [72]TL Tran, T Bek, M la Cour, JU Prause, S Hamann, S Heegaard. Aquaporin-1 Expression in Retinal Pigment Epithelial Cells Overlying Retinal Drusen . Ophthalmic Res 55:180-184 (2016)

  • [73]RJ Castellani, H-G Lee, X Zhu, G Perry, MA Smith. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 67, 523-531 (2008)

  • [74]A Lorenzo, BA Yankner. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red . Proc Natl Acad Sci USA 91, 12243-12247 (1994)

  • [75]G Forloni, R Chiesa, S Smiroldo, L Verga, M Salmona, F Tagliavini, N Angeretti. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport 4, 523-526 (1993)

  • [76]P Eikelenboom, R Veerhuis, W Scheper, AJM Rozemuller, WA van Gool, JJM Hoozemans. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113, 1685-1695 (2006)

  • [77]RJ Mark, EM Blanc, MP Mattson. Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol Neurobiol 12, 211-224 (1996)

  • [78]B Bandyopadhyay, G Li, H Yin, J Kuret. Tau aggregation and toxicity in a cell culture model of tauopathy. J Biol Chem 282, 16454-16464 (2007)

  • [79]A Nunomura, RJ Castellani, X Zhu, PI Moreira, G Perry, MA Smith. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65, 631-641 (2006)

  • [80]RE Mrak, WST Griffin. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol 66, 683-686 (2007)

  • [81]JM Isas, V Luibl, L V Johnson, R Kayed, R Wetzel, CG Glabe, R Langen, J Chen. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 51, 1304-1310 (2010)

  • [82]KU Löffler, DP Edward, MO Tso. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci 36, 24-31 (1995)

  • [83]RA Crowther. Structural aspects of pathology in Alzheimer's disease. Biochim Biophys Acta 1096, 1-9 (1990)

  • [84]T Dentchev, AH Milam, VM-Y Lee, JQ Trojanowski, JL Dunaief. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9, 184-190 (2003)

  • [85]R Guymer, T Cipriani, KD Rittenhouse, L Lim, LD Robman, W Li, W Wang, S Deng, P Banerjee. Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration. Graefe's Arch Clin Exp 253, 1347-1354 (2015)

  • [86]D. Harman. Aging: a theory based on free radical and radiation chemistry. J Gerontol 11, 298-300 (1956)

  • [87]NG Bazan. Is There a Molecular Logic That Sustains Neuronal Functional Integrity and Survival?Lipid Signaling Is Necessary for Neuroprotective Neuronal Transcriptional Programs. Mol Neurobiol 50, 1-5 (2014)

  • [88]EG McGeer, A Klegeris, PL McGeer. Inflammation, the complement system and the diseases of aging. Neurobiology of Aging Dec;26 Suppl 1, 94-97 (2005)

  • [89]Y Cai, J Arikkath, L Yang, M-L Guo, P Periyasamy, S Buch. Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders. Autophagy 12, 225-244 (2016)

  • [90]GJ Kotwal, N Fernando, J Zhou, K. Valter Exploring the potential benefits of vaccinia virus complement control protein in controlling complement activation in pathogenesis of the central nervous system diseases. Mol Immunol 61, 204-209 (2014)

  • [91]JM Sivak. The aging eye: Common degenerative mechanisms between the Alzheimer's brain and retinal disease. Investig Ophthalmol Vis Sci 54, 871-880 (2013)

  • [92]L Feng, F Wang. Detecting A-beta Deposition and RPE Cell Senescence in the Retinas of SAMP8 Mice. Discov Med 21, 149-158 (2016)

  • [93]EY Chew, TE Clemons, E Agrón, LJ Launer, F Grodstein, PS Bernstein, Age-Related Eye Disease Study 2 (AREDS2) Research Group. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA 314, 791-801 (2015)

  • [94]JM Nolan, E Loskutova, A Howard, R Mulcahy, R Moran, J Stack, M Bolger, RF Coen, J Dennison, KO Akuffo, N Owens, R Power, D Thurnham, S Beatty. The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial . J Alzheimers Dis 44, 1157-1169 (2015)

  • [95]O Butovsky, M Koronyo-Hamaoui, G Kunis, E Ophir, G Landa, H Cohen, M Schwartz. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 103, 11784-11789 (2006)

  • [96]G Landa, O Butovsky, J Shoshani, M Schwartz, A Pollack. Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res 33, 1011-1013 (2008)

  • [97]FL Ferris, CP Wilkinson, A Bird, U Chakravarthy, E Chew, K Csaky, SR Sadda. Clinical Classification of Age-related Macular Degeneration. Ophthalmology 120, 844-851 (2013)

  • [98]M Yuzawa. (Polypoidal choroidal vasculopathy). Nihon Ganka Gakkai Zasshi 116, 200-231 (2012)

  • [99]T Iida. Polypoidal choroidal vasculopathy with an appearance similar to classic choroidal neovascularisation on fluorescein angiography. Br J Ophthalmol 91, 1103-1104 (2007)

  • [100]PL McGeer, EG McGeer. Inflammation and the degenerative diseases of aging. in Ann NY Acad Sci Dec 1035, 104-116 (2004)

  • [101]GJ McKay, CC Patterson, U Chakravarthy, S Dasari, CC Klaver, JR Vingerling, L Ho, PTVM de Jong, AE Fletcher, IS Young, JH Seland, M Rahu, G Soubrane, L Tomazzoli, F Topouzis, J Vioque, AD Hingorani, R Sofat, M Dean, J Sawitzke, JM Seddon, I Peter, AR Webster, AT Moore, JR Yates, V Cipriani, LG Fritsche, BH Weber, CN Keilhauer, AJ Lotery, S Ennis, ML Klein, PJ Francis, D Stambolian, A Orlin, MB Gorin, DE Weeks, CL Kuo, A Swaroop, M Othman, A Kanda, W Chen, GR Abecasis, AF Wright, C Hayward, PN Baird, RH Guymer, J Attia, A Thakkinstian, G Silvestri. Evidence of association of APOE with age-related macular degeneration - a pooled analysis of 15 studies. Hum Mutat 32, 1407-1416 (2011)

  • [102]PP Connell, PA Keane, EC O'Neill, RW Altaie, E Loane, K Neelam, JM Nolan, S Beatty. Risk factors for age-related maculopathy . J Ophthalmol 2009, 360764 (2009)

  • [103]Q-Y Zhang, L-J Tie, S-S Wu, P-L Lv, H-W Huang, W-Q Wang, H Wang, L Ma. Overweight, Obesity, and Risk of Age-Related Macular Degeneration . Invest Ophthalmol Vis Sci 57, 1276-1283 (2016)

  • [104]A Cougnard-Grégoire, M-N Delyfer, J-F Korobelnik, M-B Rougier, F Malet, M Le Goff, J-F Dartigues, J Colin, P Barberger-Gateau, C. Delcourt Long-term blood pressure and age-related macular degeneration: the ALIENOR study. Invest Ophthalmol Vis Sci 54, 1905-1912 (2013)

  • [105]NE Shepardson, GM Shankar, DJ Selkoe. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 68, 1385-1392 (2011)

  • [106]MN Sabbagh, K Thind, DL Sparks. On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks. Alzheimer Dis Assoc Disord 23, 303-305 (2009)

  • [107]CR Hooijmans, AJ Kiliaan. Fatty acids, lipid metabolism and Alzheimer pathology. Eur J Pharmacol 585, 176-196 (2008)

  • [108]TJ Littlejohns, WE Henley, IA Lang, C Annweiler, O Beauchet, PHM Chaves, L Fried, BR Kestenbaum, LH Kuller, KM Langa, Lopez OL, Kos K, Soni M, Llewellyn DJ. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 83, 920-928 (2014)

  • [109]C Annweiler, M Drouet, GT Duval, P-Y Paré, S Leruez, M Dinomais, D Milea. Circulating vitamin D concentration and age-related macular degeneration: Systematic review and meta-analysis. Maturitas 88, 101-112 (2016)

  • [110]Y-S Ho, D Chun-Hei Poon, T-F Chan, R Chuen-Chung Chang. From Small to Big Molecules: How Do We Prevent and Delay the Progression of Age-Related Neurodegeneration? Curr Pharm Des 18, 15-26 (2012)

  • [111]ST Pendlebury, PM. Rothwell Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet 8, 1006-1018 (2009)

  • [112]ZS Tan, A Beiser, RS Vasan, R Au, S Auerbach, DP Kiel, PA Wolf, S Seshadri. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 168, 1514-1520 (2008)

  • [113]L Chaker, GHS Buitendijk, A Dehghan, M Medici, A Hofman, JR Vingerling, OH Franco, CCW Klaver, RP Peeters. Thyroid function and age-related macular degeneration: a prospective population-based cohort study--the Rotterdam Study. BMC Med 13, 94 (2015)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review
Associations of Alzheimer’s disease with macular degeneration
Leonardo Biscetti 1, Elisa Luchetti 1, Andrea Vergaro 2, Paola Menduno 2, Carlo Cagini 2, Lucilla Parnetti 1,*
Affiliations
Article Info

1 Centre of Memory Disturbances, Section of Neurology, University Hospital of Perugia, Perugia, Italy

2 Department of Surgery and Biomedical Science, University of Perugia Ospedale S. Maria della Misericordia, Perugia, Italy

*Author to whom correspondence should be addressed.

 

Abstract

There is growing evidence of epidemiological, genetic, molecular and clinical links between Alzheimer’s disease (AD) and age-related macular degeneration (AMD). Major interest in the relationship between AD and AMD has derived from the evidence that beta-amyloid, the main component of senile plaques, the hallmark of AD, is also an important component of drusen, the hallmark of AMD. This finding has a great potential in the present era of anti-amyloid agents for the treatment of AD. The connection between AD and AMD is also supported by the evidence that the two diseases share other pathophysiological factors, such as oxidative stress and neuroinflammation. Accordingly, a few clinical trials have evaluated the efficacy of antioxidants on visual and cognitive performance in patients presenting both disorders. In this review, we summarize the pathophysiological and clinical evidence of the relationship between these two age-related disorders. Considering the increasing prevalence of both conditions along with the aging of the population, further investigations of this important issue are highly needed.

Keywords

  • Alzheimer’s Disease
  • Age-Related Macular Degeneration
  • Beta Amyloid
  • Drusen
  • Review

References